5 Small Drug Stocks to Buy as Trump Gets Re-Elected
Innovation is at its peak for the Zacks Medical-Drugs industry. MDGL, CORT, CPRX, LRMR and TBPH may prove to be good additions to one's portfolio.
Corcept Therapeutics Stock Surges 61% in 2024: A Must Buy?
Investors should invest in CORT right now as the stock is doing extremely well in 2024 and its prospects look even brighter.
Here is Why Growth Investors Should Buy Corcept (CORT) Now
Corcept (CORT) could produce exceptional returns because of its solid growth attributes.
Corcept (CORT) Upgraded to Strong Buy: Here's Why
Corcept (CORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Best Momentum Stocks to Buy for November 5th
CORT, ZBRA and QUAD made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 5, 2024.
Corcept Therapeutics Incorporated (CORT) Soars to 52-Week High, Time to Cash Out?
Corcept (CORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Wall Street Analysts Believe Corcept (CORT) Could Rally 56.66%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 56.7% in Corcept (CORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Recent Price Trend in Corcept (CORT) is Your Friend, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Corcept (CORT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Earnings Estimates Moving Higher for Corcept (CORT): Time to Buy?
Corcept (CORT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View
CORT beats on both earnings and sales in the third quarter of 2024. The company increases the revenue guidance for 2024.
Corcept Therapeutics Incorporated (CORT) Q3 2024 Earnings Call Transcript
Corcept Therapeutics Incorporated (NASDAQ:CORT ) Q3 2024 Earnings Conference Call October 30, 2024 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Charlie Robb - Chief Business Officer Joe Belanoff - Chief Executive Officer Conference Call Participants David Amsellem - Piper Sandler Matt Kaplan - Ladenburg Swayampakula Ramakanth - H. C. Wainwright Joon Lee - Truist Operator Good day and thank you for standing by.
Corcept Therapeutics (CORT) Tops Q3 Earnings and Revenue Estimates
Corcept Therapeutics (CORT) came out with quarterly earnings of $0.41 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.28 per share a year ago.
